Summary & Overview
CPT 80306: Presumptive Drug Test by Instrument-Assisted Immunoassay
CPT code 80306 represents instrument-read presumptive drug testing—typically immunoassay screening performed by a laboratory analyst to detect one or more drug classes on a single date. This service is a common first-line laboratory screen used across clinical, occupational, and forensic settings to identify potential drug exposures prior to confirmatory testing. Nationally, presumptive drug testing is a high-volume laboratory service with implications for clinical workflows, laboratory billing, and payer coverage policies.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of what CPT code 80306 covers, how it is typically billed and reported in laboratory settings, and where it fits in the testing pathway between initial screen and confirmatory assays. The publication outlines typical sites of service and the service type to clarify clinical context.
The report provides practical benchmarks and policy context relevant to payers and providers: typical utilization scenarios, coding relationships to confirmatory testing, and considerations for documentation and claims processing. Data not available in the input will be identified as such in relevant sections.
Billing Code Overview
CPT code 80306 describes a presumptive drug test or tests performed by a laboratory analyst using instrument-assisted direct optical observation, commonly via immunoassay. The procedure screens for one or more drug classes on a single date using methods that the analyst can read with instruments rather than solely by visual inspection.
Service type: Laboratory diagnostic screening (presumptive drug testing).
Typical site of service: Clinical laboratory or outpatient laboratory facility, including hospital laboratories and independent reference labs where instrument-assisted immunoassay screening is performed.
Clinical & Coding Specifications
Clinical Context
A 32-year-old patient presents to an outpatient addiction medicine clinic for routine monitoring during a medication-assisted treatment program. A urine sample is collected and sent to the clinic laboratory. The lab analyst performs a presumptive instrument-read urine drug screen using an immunoassay panel that simultaneously screens multiple drug classes (e.g., opioids, benzodiazepines, amphetamines, cocaine metabolites, THC). Results are reviewed by the clinic and documented in the medical record the same day; any presumptive positives may prompt confirmatory testing by a reference laboratory. Typical workflow: sample collection at point of care or sent to lab → accessioning and labeling → instrument-assisted immunoassay presumptive screen (80306) → result entry and clinician review → reflex confirmatory testing if required → clinical follow-up and documentation.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | When only the professional (interpretation) portion of a lab test is reported separate from the technical component |
52 | Reduced services |